when you stop taking tirzepatide what happens Mounjaro® Stopping Tirzepatide: What To Expect

Risk of hepatocellular carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis

Results vary, but clinical studies show that patients combining GLP-1 Agonist with lifestyle changes can achieve significant weight loss, often averaging around 15% of their starting body weight over about a year

It will also come down to what the patient needs in terms of weight loss

Date: June 14, 2026 Source: The Endocrine Society Summary: People taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may be losing pounds, but they could also be moving less